Skip to content
← All treatment topics

TREATMENT READING

Laryngeal Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

52 sections
  1. Treatment Option Overview for Laryngeal Cancer
  2. Surgery and/or Radiation Therapy
  3. Concurrent Chemoradiation Therapy
  4. Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation Therapy
  5. Fluorouracil dosing
  6. Altered Fractionation Versus Standard Fractionation Radiation Therapy
  7. Surgery Followed by Postoperative Radiation Therapy (PORT) With or Without Chemotherapy for Patients With Locally Advanced Disease
  8. Treatment of Stage I Laryngeal Cancer
  9. Supraglottis
  10. Glottis
  11. Subglottis
  12. Treatment of Stage II Laryngeal Cancer
  13. Supraglottis
  14. Glottis
  15. Subglottis
  16. Treatment of Stage III Laryngeal Cancer
  17. Supraglottis
  18. Glottis
  19. Subglottis
  20. Treatment of Stage IV Laryngeal Cancer
  21. Supraglottis
  22. Glottis
  23. Subglottis
  24. Treatment of Metastatic and Recurrent Laryngeal Cancer
  25. Treatment Options for Metastatic and Recurrent Laryngeal Cancer
  26. Chemotherapy
  27. Immunotherapy
  28. Pembrolizumab
  29. Nivolumab
  30. Certain factors affect prognosis (chance of recovery) and treatment options.
  31. After surgery, the stage of the cancer may change and more treatment may be needed.
  32. Laryngeal cancer can recur (come back) after it has been treated.
  33. Treatment Option Overview
  34. Key Points
  35. There are different types of treatment for patients with laryngeal cancer.
  36. The following types of treatment are used:
  37. Radiation therapy
  38. Surgery
  39. Chemotherapy
  40. Immunotherapy
  41. New types of treatment are being tested in clinical trials.
  42. Targeted therapy
  43. Radiosensitizers
  44. Treatment for laryngeal cancer may cause side effects.
  45. Patients may want to think about taking part in a clinical trial.
  46. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  47. Follow-up tests may be needed.
  48. Treatment of Stage I Laryngeal Cancer
  49. Treatment of Stage II Laryngeal Cancer
  50. Treatment of Stage III Laryngeal Cancer
  51. Treatment of Stage IV Laryngeal Cancer
  52. Treatment of Metastatic and Recurrent Laryngeal Cancer

Health professional

Treatment Option Overview for Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Laryngeal Cancer

Surgery and/or Radiation Therapy

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Surgery and radiation therapy have been the standard treatments for laryngeal cancer. However, outcome data from randomized trials are limited. Studies have attempted to evaluate the use of surgery or radiation but have been underpowered.[1] Selection of primary surgery versus radiation therapy–based treatment should be made in a multidisciplinary setting with consideration of disease stage, comorbidities, and functional status, including voice and swallowing outcomes and lung capacity.

Sources: 1

Small superficial cancers without laryngeal fixation or lymph node involvement are successfully treated by radiation therapy or surgery alone, including laser excision surgery. Radiation therapy may be selected to preserve the voice and to reserve surgery for salvaging failures. The radiation field and dose are determined by the location and size of the primary tumor. A variety of curative surgical procedures are also recommended for laryngeal cancers, some of which preserve vocal function. An appropriate surgical procedure must be considered for each patient, given the anatomical problem, performance status, and clinical expertise of the treatment team. Advanced laryngeal cancers are often treated by combining radiation with concurrent chemotherapy for larynx preservation and total laryngectomy for bulky T4 disease or salvage.[2-4]

Sources: 2 · 4

Evaluation of treatment outcome can be reported in various ways: locoregional control, disease-free survival, determinate survival, and overall survival (OS) at 2 to 5 years. Preservation of voice is an important parameter to evaluate. Outcome should be reported after initial surgery, initial radiation, planned combined treatment, or surgical salvage of radiation failures. Primary source material should be consulted to review these differences.

A review of published clinical results of definitive radiation therapy for head and neck cancer suggests a significant loss of local control when radiation therapy was prolonged. Extending standard treatment schedules should be avoided whenever possible.[5,6]

Sources: 5 · 6

Radiation therapy has not been directly compared with endolaryngeal surgery (with or without laser) for the treatment of patients with early-stage laryngeal cancer. The evidence is insufficient to show a clear difference in local control or OS for these two treatment options. Retrospective data suggest that, compared with surgery, radiation therapy might cause less perturbation of voice quality without a significant difference in patient perception.[7]

Sources: 7

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Laryngeal Cancer

Concurrent Chemoradiation Therapy

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Concurrent chemoradiation therapy is a standard treatment option for patients with locally advanced (stage III and stage IV) laryngeal cancer.

Evidence (concurrent chemoradiation therapy):

A meta-analysis of 93 randomized prospective head and neck cancer trials published between 1965 and 2000 showed the following:[8][Level of evidence B4]

Sources: 8 · Level of evidence B4

A meta-analysis of 93 randomized prospective head and neck cancer trials published between 1965 and 2000 showed the following:[8][Level of evidence B4]

The subset of patients receiving chemotherapy and radiation therapy had a 4.5% absolute survival advantage.

Patients who received concurrent chemotherapy had a greater survival benefit than those who received neoadjuvant chemotherapy.

In a randomized trial of patients with locally advanced head and neck cancer, curative-intent radiation therapy alone (213 patients) was compared with radiation therapy plus weekly cetuximab (211 patients).[9] The initial dose of cetuximab was 400 mg/m2 of body-surface area 1 week before radiation therapy was started, followed by a weekly dose of 250 mg/m2 of body-surface area for the duration of the radiation therapy. This study allowed altered-fractionation regimens to be used in both arms.[9,10][Level of evidence A1]

Sources: 9 · 9 · 10 · Level of evidence A1

In a randomized trial of patients with locally advanced head and neck cancer, curative-intent radiation therapy alone (213 patients) was compared with radiation therapy plus weekly cetuximab (211 patients).[9] The initial dose of cetuximab was 400 mg/m2 of body-surface area 1 week before radiation therapy was started, followed by a weekly dose of 250 mg/m2 of body-surface area for the duration of the radiation therapy. This study allowed altered-fractionation regimens to be used in both arms.[9,10][Level of evidence A1]

At a median follow-up of 54 months, patients treated with cetuximab and radiation therapy demonstrated significantly higher progression-free survival (PFS) (hazard ratio [HR] for disease progression or death, 0.70; P = .006).

Patients in the cetuximab arm experienced higher rates of acneiform rash and infusion reactions, although the incidence of other grade 3 or higher toxicities, including mucositis, did not differ significantly between the two groups.

For more information about oral toxicities, see Oral Complications of Cancer Therapies.

Sources: Oral Complications of Cancer Therapies

Health professional · Treatment Option Overview for Laryngeal Cancer

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation Therapy

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

In a meta-analysis of five randomized trials, a total of 1,022 patients with locally advanced head and neck squamous cell cancer were randomly assigned to receive either neoadjuvant chemotherapy with TPF (docetaxel, cisplatin, and fluorouracil [5-FU]) followed by concurrent chemoradiation therapy or concurrent chemoradiation therapy alone. The analysis failed to show an OS (HR, 1.01; 95% confidence limits [CLs], 0.84–1.21; P = .92) or PFS (HR, 0.91; 95% CLs, 0.75–1.1; P = .32) advantage for neoadjuvant chemotherapy using the TPF regimen over concurrent chemoradiation therapy alone.[11][Level of evidence A1]

Sources: 11 · Level of evidence A1

Evidence (neoadjuvant chemotherapy followed by concurrent chemoradiation therapy):

The Department of Veterans Affairs (VA) Laryngeal Cancer Study Group directly compared chemotherapy followed by radiation therapy versus up-front surgery with postoperative radiation therapy. A total of 332 patients were randomly assigned to either three cycles of chemotherapy (cisplatin and 5-FU) and radiation therapy or surgery and radiation therapy.[12]

Sources: 12

The Department of Veterans Affairs (VA) Laryngeal Cancer Study Group directly compared chemotherapy followed by radiation therapy versus up-front surgery with postoperative radiation therapy. A total of 332 patients were randomly assigned to either three cycles of chemotherapy (cisplatin and 5-FU) and radiation therapy or surgery and radiation therapy.[12]

After two cycles of chemotherapy, the clinical tumor response was complete in 31% of the patients, and there was a partial response in 54% of the patients. Survival was similar in both arms; however, larynx preservation was possible in 64% of the patients in the chemotherapy-followed-by-radiation therapy arm.

The VA study was followed by a randomized study, RTOG 9111 (NCT00002496), in which the laryngeal preservation arm of the VA study was compared with the concurrent chemoradiation therapy and radiation therapy-alone arms. The primary end point was laryngectomy-free survival.[4] RTOG 9111 evaluated 547 patients with locally advanced laryngeal cancer who were enrolled between August 1992 and May 2000, with a median follow-up for surviving patients of 10.8 years (range, 0.07–17 years). Three regimens were compared, including neoadjuvant chemotherapy plus radiation therapy, concurrent chemoradiation therapy, and radiation therapy alone.

Sources: RTOG 9111 · 4

The VA study was followed by a randomized study, RTOG 9111 (NCT00002496), in which the laryngeal preservation arm of the VA study was compared with the concurrent chemoradiation therapy and radiation therapy-alone arms. The primary end point was laryngectomy-free survival.[4] RTOG 9111 evaluated 547 patients with locally advanced laryngeal cancer who were enrolled between August 1992 and May 2000, with a median follow-up for surviving patients of 10.8 years (range, 0.07–17 years). Three regimens were compared, including neoadjuvant chemotherapy plus radiation therapy, concurrent chemoradiation therapy, and radiation therapy alone.

Both chemotherapy regimens improved laryngectomy-free survival compared with radiation therapy alone (neoadjuvant chemotherapy vs. radiation therapy alone, HR, 0.75; 95% confidence interval [CI], 0.59–0.95; P = .02; concurrent chemotherapy vs. radiation therapy alone, HR, 0.78; 95% CI, 0.78–0.98; P = .03).

Concurrent radiation therapy plus cisplatin resulted in a statistically significantly higher percentage of patients with an intact larynx at 10 years (67.5% for patients who had neoadjuvant chemotherapy; 81.7% for patients who had concurrent chemotherapy; and 63.8% for patients who received radiation therapy alone); 80% of laryngectomies were performed during the first 2 years (84 laryngectomies during year 1 and 35 laryngectomies during year 2).

Concurrent cisplatin with radiation therapy resulted in a 41% reduction in risk of locoregional failure compared with radiation therapy alone (HR, 0.59; 95% CI, 0.43–0.82; P = .0015) and a 34% reduction in risk compared with neoadjuvant chemotherapy (HR, 0.66; 95% CI, 0.48–0.92; P = .004). Both chemotherapy regimens had a lower incidence of distant metastases, although this did not reach statistical significance compared with radiation therapy alone.

The 10-year cumulative rates of late toxicity (grades 3–5) were 30.6% for neoadjuvant chemotherapy, 33.3% for concurrent chemotherapy, and 38% for radiation therapy alone, and were not significantly different between the arms.

OS was not significantly different between the groups, although there was possibly a worse outcome in the concurrent groups compared with the neoadjuvant chemotherapy group (HR, 1.25; 95% CI, 0.98–1.61; P = .08). The OS rates were 58% (5 year) and 39% (10 year) for neoadjuvant chemotherapy, 55% (5 year) and 28% (10 year) for concurrent chemoradiation therapy, and 54% (5 year) and 32% (10 year) for radiation therapy alone.

The number of deaths not attributed to larynx cancer or treatment were higher with concurrent chemotherapy (30.8% vs. 20.8% with neoadjuvant chemotherapy and 16.9% with radiation alone), because after approximately 4.5 years, the survival curves began to separate and favor neoadjuvant chemotherapy, although the difference was not statistically significant.

Health professional · Treatment Option Overview for Laryngeal Cancer / Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation Therapy

Fluorouracil dosing

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[13,14] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[13-15] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[16-18] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[19] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[20]

Sources: 13 · 14 · 13 · 15 · 16 · 18 · 19 · 20

Health professional · Treatment Option Overview for Laryngeal Cancer

Altered Fractionation Versus Standard Fractionation Radiation Therapy

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Radiation therapy alone with altered fractionation may be used for patients with locally advanced laryngeal cancer who are not candidates for chemotherapy. Altered fractionation radiation therapy yields a higher locoregional control rate compared with standard fractionated radiation therapy for patients with stage III and stage IV head and neck cancer.

Evidence (altered fractionation vs. standard fractionation radiation therapy):

The randomized RTOG-9003 trial (NCT00771641) included four radiation therapy treatment arms:[21,22][Level of evidence A1]In a long-term analysis, the three investigational arms were compared with SFX.

Sources: RTOG-9003 · 21 · 22 · Level of evidence A1

The randomized RTOG-9003 trial (NCT00771641) included four radiation therapy treatment arms:[21,22][Level of evidence A1]In a long-term analysis, the three investigational arms were compared with SFX.

Standard fractionation (SFX) to 70 Gy in 35 daily fractions for 7 weeks.

Hyperfractionation (HFX) to 81.6 Gy in 68 twice-daily fractions for 7 weeks.

Accelerated fractionation split course (AFX-S) to 67.2 Gy in 42 fractions for 6 weeks with a 2-week rest after 38.4 Gy.

Accelerated concurrent boost fractionation (AFX-C) to 72 Gy in 42 fractions for 6 weeks.

Only the HFX arm showed superior locoregional control and survival at 5 years compared with the SFX arm (HR, 0.79; 95% CI, 0.62–1.00; P = .05).

AFX-C was associated with increased late toxicity compared with SFX.

The following results were shown in a meta-analysis of 15 randomized trials with a total of 6,515 patients and a median follow-up of 6 years involving the assessment of HFX or AFX-S for patients with stage III and stage IV oropharyngeal cancer:[23][Level of evidence A1]

Sources: 23 · Level of evidence A1

The following results were shown in a meta-analysis of 15 randomized trials with a total of 6,515 patients and a median follow-up of 6 years involving the assessment of HFX or AFX-S for patients with stage III and stage IV oropharyngeal cancer:[23][Level of evidence A1]

There was a significant survival benefit with altered-fractionated radiation therapy and a 3.4% absolute benefit at 5 years (HR, 0.92; 95% CI, 0.86–0.97; P = .003).

Altered-fractionation radiation therapy improves locoregional control, with greater benefit shown in younger patients.

HFX demonstrated a greater survival benefit (8% at 5 years) than did AFX-S (2% with accelerated fractionation without total dose-reduction and 1.7% with total dose-reduction at 5 years; P = .02).

An additional late effect from radiation therapy is hypothyroidism, which occurs in 30% to 40% of patients who have received external-beam radiation therapy to the entire thyroid gland. Thyroid function testing of patients is a consideration before therapy and as part of posttreatment follow-up.[24,25]

Sources: 24 · 25

Prospective data from two randomized controlled trials reported the incidence of hypothyroidism.[26]

Sources: 26

At a median follow-up of 41 months, 55.1% of the patients developed hypothyroidism (39.3% subclinical, 15.7% biochemical).

Patients who underwent intensity-modulated radiation therapy (IMRT) had higher subclinical hypothyroidism (51.1% vs. 27.3%; P = .021), peaking around 1 year after radiation therapy.

Younger age, hypopharynx/larynx primary, node positivity, higher dose/fraction (IMRT arm), and D100 were statistically significant factors for developing hypothyroidism.[26][Level of evidence A3]

Sources: 26 · Level of evidence A3

For patients with well-lateralized oropharyngeal cancer, such as a T1 or T2 tonsil primary tumor with limited extension into the palate or tongue base and limited ipsilateral lymph node involvement without extracapsular extension, elective treatment to the ipsilateral lymph nodes results in only minimal risk of spread to the contralateral neck.[27] For T3 and T4 tumors that are midline or approach the midline, bilateral nodal treatment is a consideration. In addition to the cervical lymph node chain, retropharyngeal lymph nodes can also be encompassed in the elective nodal treatment.

Sources: 27

Health professional · Treatment Option Overview for Laryngeal Cancer

Surgery Followed by Postoperative Radiation Therapy (PORT) With or Without Chemotherapy for Patients With Locally Advanced Disease

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

New surgical techniques for resection and reconstruction that provide access and functional preservation have extended the surgical options for patients with stage III or stage IV laryngeal cancer. Specific surgical procedures and their modifications are not described here because of the wide variety of surgical approaches, the variety of opinions about the role of modified neck dissections, and the multiple reconstructive techniques that may give the same results. This group of patients is managed by head and neck surgeons who are skilled in the multiple procedures available and are actively and frequently involved in the care of these patients.

Depending on pathological findings after primary surgery, PORT with or without chemotherapy is used in the adjuvant setting for the following histological findings:

T4 disease.

Perineural invasion.

Lymphovascular invasion.

Positive margins or margins less than 5 mm.

Extracapsular extension of a lymph node.

Two or more involved lymph nodes.

The addition of chemotherapy to PORT for laryngeal cancer squamous cell carcinoma demonstrates a locoregional control and OS benefit compared with radiation therapy alone in patients who have high-risk pathological risk factors, extracapsular extension of a lymph node, or positive margins, based on a pooled analysis of the EORTC-22931 [NCT00002555] and RTOG-9501 [NCT00002670] studies.[28-31][Level of evidence A1]

Sources: EORTC-22931 · RTOG-9501 · 28 · 31 · Level of evidence A1

For patients with intermediate pathological risk factors, the addition of cisplatin chemotherapy given concurrently with PORT is unclear. Intermediate pathological risk factors include:

T3 and T4 disease (or stage III and stage IV disease).

Perineural infiltration.

Vascular embolisms.

Clinically enlarged level IV–V lymph nodes secondary to tumors arising in the oral cavity or oropharynx.

Two or more histopathologically involved lymph nodes without extracapsular extension.

Close margins less than 5 mm.

The addition of cetuximab with radiation therapy in the postoperative setting for these intermediate pathological risk factors is being tested in a randomized trial (RTOG-0920 [NCT00956007]).

Sources: RTOG-0920

The incidence of lymph node metastases in patients with stage I glottic cancer ranges from 0% to 2%; for more advanced disease, such as stage II, 10%; and for stage III glottic, 15%. Thus, there is no need to treat glottic cancer cervical lymph nodes electively in patients with stage I tumors and small stage II tumors. Elective neck radiation is a consideration for T3 or T4 glottic tumors or T1 to T4 supraglottic tumors.[32]

Sources: 32

For patients with cancer of the subglottis, combined modality therapy is generally preferred for the uncommon small lesions (i.e., stage I or stage II); however, radiation therapy alone may be used.

Patients who smoke during radiation therapy appear to have lower response rates and shorter survival durations than those who do not.[33] Such patients should be counseled on smoking cessation before beginning radiation therapy.

Sources: 33

Health professional

Treatment of Stage I Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage I Laryngeal Cancer

Supraglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage I cancer of the supraglottis include:

External-beam radiation therapy (EBRT) therapy alone.

Supraglottic laryngectomy. Total laryngectomy may be reserved for patients unable to tolerate potential respiratory complications of surgery or the supraglottic laryngectomy.

Health professional · Treatment of Stage I Laryngeal Cancer

Glottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage I cancer of the glottis include:

Radiation therapy.[1-4]

Sources: 1 · 4

Endoscopic CO2 laser excision.[5]

Sources: 5

Cordectomy for very carefully selected patients with limited and superficial T1 lesions.[6,7]

Sources: 6 · 7

Partial or hemilaryngectomy or total laryngectomy, depending on anatomical considerations.

Health professional · Treatment of Stage I Laryngeal Cancer

Subglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage I cancer of the subglottis include:

Lesions can be treated successfully by radiation therapy alone with preservation of normal voice.

Surgery is reserved for failure of radiation therapy or for patients who cannot be easily assessed for radiation therapy.

For more information, see the Treatment Option Overview for Laryngeal Cancer section.

Sources: Treatment Option Overview for Laryngeal Cancer

Radiation therapy

Transoral CO2 laser excision versus EBRT

Selection of treatment should include an evaluation of voice function and quality after treatment. Endoscopic CO2 laser resections may also achieve similar results in terms of local control and function [8] compared with radiation therapy, although no randomized studies have been performed.[9]

Sources: 8 · 9

Evidence (transoral CO2 laser excision vs. EBRT):

A meta-analysis examined oncologic control in 22 consecutive case series.

A meta-analysis examined oncologic control in 22 consecutive case series.

No clear differences were demonstrated between transoral CO2 laser excision and EBRT in terms of local control (odds ratio [OR], 0.81; 95% confidence interval [CI], 0.51–1.3) and laryngectomy-free survival (OR, 0.84; 95% CI, 0.42–1.66).

There was a trend for improved posttreatment voice quality with radiation therapy. Transoral CO2 laser–excision surgery dominates radiation therapy from a cost-utility standpoint.[5][Level of evidence B4]

Sources: 5 · Level of evidence B4

Conventional radiation therapy versus hypofractionated radiation therapy

Conventional and hypofractionated radiation therapy regimens have been studied regarding radiation-dose fractionation for patients with early-stage larynx cancer.

Evidence (conventional radiation therapy vs. hypofractionated radiation therapy):

In a randomized study of patients with early-stage larynx cancer, patients were assigned to standard fractionation in 2 Gy daily fractions or a hypofractionated regimen of 2.25 Gy daily; 82 patients were allocated to a conventional fractionation (CONV) arm (66 Gy/33 fractions for T1 and 70 Gy/35 fractions for T2), with 74 patients to the hypofractionation (HYPO) arm (63 Gy/28 fractions for T1 and 67.5 Gy/30 fractions for T2).[10] The study was underpowered and closed early because of a lack of accrual, although no statistically significant differences were seen between treatment arms in terms of local progression-free survival (PFS).Earlier single-institution reports support hypofractionated regimens using 2.25 Gy per fraction for early T1 and T2 larynx cancer with high local control rates.[11][Level of evidence C3]

Sources: 10 · 11 · Level of evidence C3

In a randomized study of patients with early-stage larynx cancer, patients were assigned to standard fractionation in 2 Gy daily fractions or a hypofractionated regimen of 2.25 Gy daily; 82 patients were allocated to a conventional fractionation (CONV) arm (66 Gy/33 fractions for T1 and 70 Gy/35 fractions for T2), with 74 patients to the hypofractionation (HYPO) arm (63 Gy/28 fractions for T1 and 67.5 Gy/30 fractions for T2).[10] The study was underpowered and closed early because of a lack of accrual, although no statistically significant differences were seen between treatment arms in terms of local progression-free survival (PFS).Earlier single-institution reports support hypofractionated regimens using 2.25 Gy per fraction for early T1 and T2 larynx cancer with high local control rates.[11][Level of evidence C3]

With a median follow-up of 67 months (range, 2–122 months), the 5-year local PFS rate was 77.8% for the CONV arm and 88.5% for the HYPO arm (hazard ratio [HR], 1.55; P = .213).

No significant difference was observed in the toxicity profile between the two arms.

In a subgroup exploratory analysis for T1a disease, the 5-year local PFS rate trended positively in the HYPO arm (76.7% vs. 93.0%; HR, 3.65; P = .056).[10][Level of evidence B1]

Sources: 10 · Level of evidence B1

Health professional

Treatment of Stage II Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage II Laryngeal Cancer

Supraglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage II cancer of the supraglottis include:

External-beam radiation therapy alone for the smaller lesions encompassing the primary disease and regional elective nodes.[1]

Sources: 1

Supraglottic laryngectomy with bilateral neck dissections, depending on location of the lesion, clinical status of the patient, and expertise of the treatment team. Careful selection must be made to ensure adequate pulmonary and swallowing function postoperatively.

Postoperative radiation therapy (PORT) is indicated for positive or close surgical margins or other adverse pathological risk factors.

Radiation therapy should be preferred because of the good results, preservation of the voice, and the possibility of surgical salvage in patients whose disease recurs locally.

Health professional · Treatment of Stage II Laryngeal Cancer

Glottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage II cancer of the glottis include:

Radiation therapy.[1-4]

Sources: 1 · 4

Endoscopic CO2 laser excision.[5]

Sources: 5

Partial or hemilaryngectomy or total laryngectomy, depending on anatomical considerations. Under certain circumstances, laser microsurgery may be appropriate.[6]

Sources: 6

Health professional · Treatment of Stage II Laryngeal Cancer

Subglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage II cancer of the subglottis include:

Lesions can be treated successfully by radiation therapy alone with preservation of normal voice.[1]

Sources: 1

Surgery is reserved for failure of radiation therapy or for patients in whom follow-up is likely to be difficult.

For more information, see the Treatment Option Overview for Laryngeal Cancer section.

Sources: Treatment Option Overview for Laryngeal Cancer

Health professional

Treatment of Stage III Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage III Laryngeal Cancer

Supraglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage III cancer of the supraglottis include:

Concurrent chemoradiation therapy can be considered for patients who would require total laryngectomy for control of disease.[1]

Sources: Concurrent chemoradiation therapy · 1

Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy. Laryngectomy is reserved for patients with less than a 50% response to chemotherapy or who have persistent disease following radiation.[1-6][Level of evidence A3]

Sources: Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy · 1 · 6 · Level of evidence A3

Definitive radiation therapy alone with altered fractionation in patients who are not candidates for concurrent chemotherapy and surgery (total laryngectomy) for salvage of radiation failures.[7]

Sources: altered fractionation · 7

Surgery with or without postoperative radiation therapy (PORT).[8]

Sources: 8

Health professional · Treatment of Stage III Laryngeal Cancer

Glottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage III cancer of the glottis include:

Concurrent chemoradiation therapy can be considered for patients who would require total laryngectomy for control of disease.[1]

Sources: Concurrent chemoradiation therapy · 1

Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy. Laryngectomy is reserved for patients with less than a 50% response to chemotherapy or who have persistent disease after radiation.[1-6]

Sources: Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy · 1 · 6

Definitive radiation therapy alone with altered fractionation in patients who are not candidates for concurrent chemotherapy and surgery (total laryngectomy) for salvage of radiation failures.[7]

Sources: altered fractionation · 7

Surgery with or without PORT.[8]

Sources: 8

Clinical trials exploring novel targeted therapy, immunotherapy, novel chemotherapy, radiosensitizers, or particle-beam radiation therapy.[9]

Sources: 9

Health professional · Treatment of Stage III Laryngeal Cancer

Subglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage III cancer of the subglottis include:

Laryngectomy plus isolated thyroidectomy and tracheoesophageal node dissection usually followed by PORT.[10]

Sources: 10

Treatment by radiation therapy alone is indicated for patients who are not candidates for surgery. Patients should be closely followed, and surgical salvage should be planned for recurrences that are local or in the neck.

Definitive radiation therapy alone with altered fractionation in patients who are not candidates for concurrent chemotherapy and surgery (total laryngectomy) for salvage of radiation failures.[6,7]

Sources: altered fractionation · 6 · 7

Induction chemotherapy followed by concomitant chemotherapy and radiation. Laryngectomy is reserved for patients with less than a 50% response to chemotherapy or who have persistent disease after radiation.[6]

Sources: Induction chemotherapy followed by concomitant chemotherapy and radiation · 6

Clinical trials exploring novel targeted therapy, immunotherapy, novel chemotherapy, radiosensitizers, or particle-beam radiation therapy.[9]

Sources: 9

For more information, see the Treatment Option Overview for Laryngeal Cancer section.

Sources: Treatment Option Overview for Laryngeal Cancer

Role of Neck Dissection in the Post-Radiation Therapy Setting

A prospective randomized trial included 564 patients with head and neck cancer and N2 or N3 disease. Patients were assigned to undergo planned neck dissection or surveillance with positron emission tomography–computed tomography (PET-CT). With a median follow-up of 36 months, PET-CT resulted in fewer neck dissections compared with the surgical arm (54 vs. 221), with a 2-year survival rate of 84.9% versus 81.5%, respectively. The hazard ratio (HR)death slightly favored PET-CT–guided surveillance and indicated noninferiority (upper boundary, 95% confidence interval for HR, <1.50; P = .004).[11][Level of evidence A1]

Sources: 11 · Level of evidence A1

Health professional

Treatment of Stage IV Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage IV Laryngeal Cancer

Supraglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage IV cancer of the supraglottis include:

Concurrent chemoradiation therapy can be considered for patients who would require total laryngectomy for control of disease, including those with nonbulky T4a disease.[1]

Sources: Concurrent chemoradiation therapy · 1

Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy. Laryngectomy is reserved for patients with less than a 50% response to chemotherapy or who have persistent disease after radiation.[1-6]

Sources: Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy · 1 · 6

Definitive radiation therapy alone in patients who are not candidates for concurrent chemotherapy and surgery (total laryngectomy) for salvage of radiation failures.[7]

Sources: 7

For patients with bulky T4 disease, surgery followed by postoperative radiation therapy (PORT) with or without concurrent chemotherapy based on pathological risk factors for large volume T4 disease.[8]

Sources: surgery followed by postoperative radiation therapy (PORT) with or without concurrent chemotherapy · 8

Clinical trials exploring novel targeted therapy, immunotherapy, novel chemotherapy, radiosensitizers, or particle-beam radiation therapy.[9]

Sources: 9

Health professional · Treatment of Stage IV Laryngeal Cancer

Glottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage IV cancer of the glottis include:

Concurrent chemoradiation therapy can be considered for patients who would require total laryngectomy for control of disease, including those with nonbulky T4a disease.[1]

Sources: Concurrent chemoradiation therapy · 1

Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy. Laryngectomy is reserved for patients with less than a 50% response to chemotherapy or who have persistent disease following radiation.[1-6]

Sources: Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy · 1 · 6

Definitive radiation therapy alone in patients who are not candidates for concurrent chemotherapy and surgery (total laryngectomy) for salvage of radiation failures.[7]

Sources: 7

For patients with bulky T4 disease, surgery (total laryngectomy) followed by PORT with or without concurrent chemotherapy based on pathological risk factors for large volume T4 disease.[8]

Sources: surgery (total laryngectomy) followed by PORT with or without concurrent chemotherapy · 8

Clinical trials exploring novel targeted therapy, immunotherapy, novel chemotherapy, radiosensitizers, or particle-beam radiation therapy.[9]

Sources: 9

Health professional · Treatment of Stage IV Laryngeal Cancer

Subglottis

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for stage IV cancer of the subglottis include:

Laryngectomy plus total thyroidectomy and bilateral tracheoesophageal node dissection usually followed by PORT with or without concurrent chemotherapy based on pathological risk factors.[10]

Sources: 10

Concurrent chemoradiation therapy can be considered for patients who would require total laryngectomy for control of disease, including those with nonbulky T4a disease.[1]

Sources: Concurrent chemoradiation therapy · 1

Clinical trials exploring novel targeted therapy, immunotherapy, novel chemotherapy, radiosensitizers, or particle-beam radiation therapy.

For more information, see the Treatment Option Overview for Laryngeal Cancer section.

Sources: Treatment Option Overview for Laryngeal Cancer

Health professional

Treatment of Metastatic and Recurrent Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Metastatic and Recurrent Laryngeal Cancer

Treatment Options for Metastatic and Recurrent Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for metastatic and recurrent laryngeal cancer include:

Surgery [1] and/or radiation therapy. Salvage is possible for failures of surgery alone or of radiation therapy alone, and further surgery [1] and/or radiation therapy should be attempted, as indicated. Selected patients may be candidates for partial laryngectomy after high-dose radiation therapy has failed.[2]

Sources: 1 · 1 · 2

Radiation therapy. Re-irradiation for laryngeal salvage following radiation therapy failure has resulted in long-term survival in a small number of patients; it may be considered for small recurrences after radiation therapy, especially in patients who refuse or are not candidates for laryngectomy.[3]

Sources: 3

Chemotherapy.

Sources: Chemotherapy

Immunotherapy.

Sources: Immunotherapy

Immunotherapy.

Pembrolizumab.

Sources: Pembrolizumab

Nivolumab.

Sources: Nivolumab

Clinical trials for patients whose disease does not respond to combined radiation therapy and surgery.

For more information, see the Treatment Option Overview for Laryngeal Cancer section.

Sources: Treatment Option Overview for Laryngeal Cancer

Health professional · Treatment of Metastatic and Recurrent Laryngeal Cancer / Treatment Options for Metastatic and Recurrent Laryngeal Cancer

Chemotherapy

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Platinum-based chemotherapy is often used as first-line treatment for patients with recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck. A response of variable duration may be achieved after systemic chemotherapy.[4]

Sources: 4

Evidence (chemotherapy):

In a phase III randomized trial of 442 patients with untreated metastatic or recurrent SCC of the head and neck, adding cetuximab to platinum plus fluorouracil (5-FU) compared with platinum plus 5-FU alone improved overall survival (OS), with a median survival of 10.1 months versus 7.4 months (hazard ratio [HR]death, 0.80; 95% confidence interval [CI], 0.64–0.99; P = .04).[5]Tumor EGFR gene copy number was not found to be a predictive biomarker for the efficacy of cetuximab plus platinum and 5-FU as first-line therapy for patients with recurrent or metastatic SCC of the head and neck.[7][Level of evidence A1]

Sources: 5 · 7 · Level of evidence A1

In a phase III randomized trial of 442 patients with untreated metastatic or recurrent SCC of the head and neck, adding cetuximab to platinum plus fluorouracil (5-FU) compared with platinum plus 5-FU alone improved overall survival (OS), with a median survival of 10.1 months versus 7.4 months (hazard ratio [HR]death, 0.80; 95% confidence interval [CI], 0.64–0.99; P = .04).[5]Tumor EGFR gene copy number was not found to be a predictive biomarker for the efficacy of cetuximab plus platinum and 5-FU as first-line therapy for patients with recurrent or metastatic SCC of the head and neck.[7][Level of evidence A1]

Quality of life was not adversely affected by adding cetuximab to this platinum-based regimen.[6]

Sources: 6

A phase III, open-label, randomized trial demonstrated improvements in progression-free survival (PFS) for patients who received afatinib compared with patients who received methotrexate.[8]

Sources: 8

A phase III, open-label, randomized trial demonstrated improvements in progression-free survival (PFS) for patients who received afatinib compared with patients who received methotrexate.[8]

After a median follow-up of 6.7 months, the median PFS was 2.6 months (95% CI, 2.0–2.7) for the afatinib group and 1.7 months (95% CI, 1.5–2.4) for the methotrexate group (HR, 0.80; 95% CI, 0.65–0.98; P = .030).

The most frequent grade 3 or grade 4 drug-related adverse events for patients treated with afatinib or methotrexate included:

A phase III, open-label, randomized trial demonstrated improvements in progression-free survival (PFS) for patients who received afatinib compared with patients who received methotrexate.[8] › The most frequent grade 3 or grade 4 drug-related adverse events for patients treated with afatinib or methotrexate included:

Rash or acne (10% for afatinib vs. 0% for methotrexate).

Diarrhea (9% for afatinib vs. 2% for methotrexate).

Stomatitis (6% for afatinib vs. 8% for methotrexate).

Fatigue (6% for afatinib vs. 3% for methotrexate).

Neutropenia (<1% for afatinib vs. 7% for methotrexate).

A phase III, open-label, randomized trial demonstrated improvements in progression-free survival (PFS) for patients who received afatinib compared with patients who received methotrexate.[8]

Overall serious adverse events occurred in 14% of patients treated with afatinib and 11% of patients treated with methotrexate.

Health professional · Treatment of Metastatic and Recurrent Laryngeal Cancer / Treatment Options for Metastatic and Recurrent Laryngeal Cancer

Immunotherapy

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Immunotherapy (inhibitor of the programmed death-ligand 1 [PD-L1] pathway) can be used after platinum-based failure in patients with metastatic or locally recurrent disease.[9,10]

Sources: 9 · 10

Health professional · Treatment of Metastatic and Recurrent Laryngeal Cancer / Treatment Options for Metastatic and Recurrent Laryngeal Cancer / Immunotherapy

Pembrolizumab

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Pembrolizumab is a monoclonal antibody and an inhibitor of the programmed death-1 (PD-1) pathway. Studies have evaluated pembrolizumab in patients with incurable metastatic or recurrent head and neck squamous cell carcinoma (SCC).

Evidence (pembrolizumab as first-line therapy):

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[11] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

Sources: KEYNOTE-048 · 11

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[11] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

At the second interim analysis, pembrolizumab alone showed improved or noninferior OS compared with cetuximab with chemotherapy. The median OS results were reported as follows:[11][Level of evidence A1]

Sources: 11 · Level of evidence A1

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[11] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population. › At the second interim analysis, pembrolizumab alone showed improved or noninferior OS compared with cetuximab with chemotherapy. The median OS results were reported as follows:[11][Level of evidence A1]

Among the population with a CPS of 20 or higher, the median OS was 14.9 months in patients who received pembrolizumab alone and 10.7 months in patients who received cetuximab with chemotherapy (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.45–0.83; P = .0007).

Among the population with a CPS of 1 or higher, the median OS was 12.3 months in patients who received pembrolizumab alone and 10.3 months in patients who received cetuximab with chemotherapy (HR, 0.78; 95% CI, 0.64–0.96; P = .0086).

Among the total population, patients who received pembrolizumab alone had noninferior OS (11.6 months) compared with patients who received cetuximab with chemotherapy (10.7 months) (HR, 0.85; 95% CI, 0.71–1.03; P = .0456).

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[11] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

Pembrolizumab with chemotherapy showed improved OS versus cetuximab with chemotherapy. The OS results were reported as follows:

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[11] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population. › Pembrolizumab with chemotherapy showed improved OS versus cetuximab with chemotherapy. The OS results were reported as follows:

At the second interim analysis, among the total population, the median OS was 13.0 months in patients who received pembrolizumab with chemotherapy and 10.7 months in patients who received cetuximab with chemotherapy (HR, 0.77; 95% CI, 0.63–0.93; P = .0034).

At the final analysis, among the population with a CPS of 20 or higher, the median OS was 14.7 months in patients who received pembrolizumab with chemotherapy and 11.0 months in patients who received cetuximab with chemotherapy (HR, 0.60; 95% CI, 0.45–0.82; P = .0004).

At the final analysis, among the population with a CPS of 1 or higher, the median OS was 13.6 months in patients who received pembrolizumab with chemotherapy and 10.4 months in patients who received cetuximab with chemotherapy (HR, 0.65; 95% CI, 0.53–0.80; P < .0001).

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[11] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

At the second interim analysis, neither pembrolizumab alone nor pembrolizumab with chemotherapy improved PFS.

At the final analysis, grade 3 or higher all-cause adverse events occurred in 164 of 300 patients (55%) in the pembrolizumab-alone group, 235 of 276 patients (85%) who received pembrolizumab with chemotherapy, and 239 of 287 patients (83%) who received cetuximab with chemotherapy.

Adverse events led to death in 25 patients (8%) in the pembrolizumab-alone group, 32 patients (12%) who received pembrolizumab with chemotherapy, and 28 patients (10%) who received cetuximab with chemotherapy.

Pembrolizumab plus a platinum and 5-FU is an appropriate first-line treatment for patients with metastatic or recurrent head and neck SCC. Pembrolizumab monotherapy is an appropriate first-line treatment for patients with PD-L1–positive metastatic or recurrent head and neck SCC. These results were confirmed at a longer median follow-up of 45 months (interquartile range, 41.0–49.2).[12]

Sources: 12

Evidence (pembrolizumab after progression on platinum-based treatment):

The phase III KEYNOTE-040 (NCT02252042) trial included patients with incurable metastatic or recurrent head and neck SCC who had received platinum-based treatment within 3 to 6 months.[9] Patients were randomly assigned to the pembrolizumab arm (200 mg every 3 weeks [247 patients]) or to the standard therapy arm of the investigator’s choice (methotrexate, docetaxel, or cetuximab [248 patients]). Patients received treatment until progression or toxicity. The maximum duration of pembrolizumab was 24 months. The primary end point was OS in the intention-to-treat population.

Sources: KEYNOTE-040 · 9

The phase III KEYNOTE-040 (NCT02252042) trial included patients with incurable metastatic or recurrent head and neck SCC who had received platinum-based treatment within 3 to 6 months.[9] Patients were randomly assigned to the pembrolizumab arm (200 mg every 3 weeks [247 patients]) or to the standard therapy arm of the investigator’s choice (methotrexate, docetaxel, or cetuximab [248 patients]). Patients received treatment until progression or toxicity. The maximum duration of pembrolizumab was 24 months. The primary end point was OS in the intention-to-treat population.

The median OS was 8.4 months in the pembrolizumab arm and 6.9 months in the standard therapy arm (HR, 0.80; 95% CI, 0.65–0.98; nominal P = .0161).[9][Level of evidence A1]

Sources: 9 · Level of evidence A1

Pembrolizumab was associated with fewer grade 3 or higher adverse events (pembrolizumab, 13% vs. standard therapy, 36%). The most common treatment-related adverse events were hypothyroidism (13%) in the pembrolizumab arm and fatigue (18%) in the standard therapy arm.

In patients who received pembrolizumab, there were four treatment-related deaths resulting from large intestinal perforation, Stevens-Johnson syndrome, and unspecified malignant progression. Two treatment-related deaths in the standard therapy arm resulted from malignant progression and pneumonia.

The PD-L1 CPS was 1 or higher in 79% of the patients in the pembrolizumab arm and 77% of the patients in the standard therapy arm.

Compared with patients treated with standard therapy, a reduced HRdeath was noted for patients who received pembrolizumab and had PD-1 expression on their tumors or in the tumor microenvironment as noted by a PD-L1 CPS of 1 or higher (HR, 0.74; 95% CI, 0.58–0.93; nominal P = .0049) or a PD-L1 tumor proportion score of 50% or higher (HR, 0.53; 95% CI, 0.35–0.81; nominal P = .0014).

Health professional · Treatment of Metastatic and Recurrent Laryngeal Cancer / Treatment Options for Metastatic and Recurrent Laryngeal Cancer / Immunotherapy

Nivolumab

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Nivolumab is a fully human immunoglobulin G4 anti–PD-1 monoclonal antibody.

Evidence (nivolumab combined with ipilimumab in patients who have not previously received systemic therapy):

The CheckMate 651 trial (NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab, cisplatin/carboplatin, and 5-FU for up to six cycles followed by cetuximab maintenance) in patients with recurrent or metastatic head and neck SCC.[13] The primary end points were OS in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. Secondary end points included OS in patients with a PD-L1 CPS of 1 or higher and PFS, objective response rate, and duration of response in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. The absence of a survival benefit for immune checkpoint inhibitors in this trial was an unexpected outcome, given the similarity of nivolumab to pembrolizumab in the studies of patients with cisplatin-refractory disease.[9,10] An editorial accompanying the CheckMate 651 trial analyzed some of the factors that may have contributed to a different result. The editorial suggested that survival in the control group, which was longer than that reported in prior studies, may have been impacted by the greater availability of second-line immunotherapy in the control group (46% in CheckMate 651 compared with 25% in the KEYNOTE-048 trial). The authors also suggested that the coadministration of ipilimumab detracted from the activity of nivolumab, as shown in the CheckMate 714 trial.[14]

Sources: CheckMate 651 · 13 · 9 · 10 · 14

The CheckMate 651 trial (NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab, cisplatin/carboplatin, and 5-FU for up to six cycles followed by cetuximab maintenance) in patients with recurrent or metastatic head and neck SCC.[13] The primary end points were OS in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. Secondary end points included OS in patients with a PD-L1 CPS of 1 or higher and PFS, objective response rate, and duration of response in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. The absence of a survival benefit for immune checkpoint inhibitors in this trial was an unexpected outcome, given the similarity of nivolumab to pembrolizumab in the studies of patients with cisplatin-refractory disease.[9,10] An editorial accompanying the CheckMate 651 trial analyzed some of the factors that may have contributed to a different result. The editorial suggested that survival in the control group, which was longer than that reported in prior studies, may have been impacted by the greater availability of second-line immunotherapy in the control group (46% in CheckMate 651 compared with 25% in the KEYNOTE-048 trial). The authors also suggested that the coadministration of ipilimumab detracted from the activity of nivolumab, as shown in the CheckMate 714 trial.[14]

Among all randomly assigned patients, there was no statistically significant difference in OS with nivolumab plus ipilimumab versus EXTREME (median OS, 13.9 vs. 13.5 months; HR, 0.95; 97.9% CI, 0.80–1.13; P = .4951). Among patients with a PD-L1 CPS of 20 or higher, there was also no statistically significant OS difference between the two treatments (median OS, 17.6 vs. 14.6 months; HR, 0.78; 97.51% CI, 0.59–1.03; P = .0469).[13][Level of evidence A1]

Sources: 13 · Level of evidence A1

In patients with a CPS of 1 or higher, the median OS was 15.7 months for patients who received nivolumab plus ipilimumab versus 13.2 months for patients who received EXTREME (HR, 0.82; 95% CI, 0.69–0.97).

Among patients with a CPS of 20 or higher, the median PFS was 5.4 months for patients who received nivolumab plus ipilimumab and 7.0 months for patients who received EXTREME. The objective response rate was 34.1% for patients who received nivolumab plus ipilimumab and 36.0% for patients who received EXTREME.

Grade 3 or 4 treatment-related adverse events occurred in 28.2% of patients who received nivolumab plus ipilimumab and 70.7% of patients who received EXTREME.

CheckMate 651 did not meet its primary end points of OS in the randomly assigned or CPS of 20 or higher populations.

CheckMate 714 (NCT02823574), a double-blind phase II trial, evaluated the clinical benefit of first-line nivolumab plus ipilimumab versus nivolumab alone in 425 patients with recurrent or metastatic head and neck SCC.[15] Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (3 mg/kg intravenously [IV] every 2 weeks) plus ipilimumab (1 mg/kg IV every 6 weeks) or nivolumab (3 mg/kg IV every 2 weeks) plus placebo. Treatment continued for up to 2 years or until disease progression, unacceptable toxic effects, or consent withdrawal. The primary end points were objective response rate and duration of response between treatment arms by blinded independent central review in the population with platinum-refractory recurrent or metastatic disease. These were patients who had recurrent disease less than 6 months after completion of platinum-based chemotherapy (adjuvant or neoadjuvant, or as part of multimodal treatment [chemotherapy, surgery, and/or radiation therapy]). Among the 241 patients (56.7%) with platinum-refractory disease, 159 were assigned to receive nivolumab plus ipilimumab and 82 were assigned to receive nivolumab alone. Among the 184 patients (43.3%) with platinum-eligible disease, 123 were assigned to receive nivolumab plus ipilimumab and 61 were assigned to receive nivolumab alone.[15][Level of evidence B3]

Sources: CheckMate 714 · 15 · 15 · Level of evidence B3

CheckMate 714 (NCT02823574), a double-blind phase II trial, evaluated the clinical benefit of first-line nivolumab plus ipilimumab versus nivolumab alone in 425 patients with recurrent or metastatic head and neck SCC.[15] Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (3 mg/kg intravenously [IV] every 2 weeks) plus ipilimumab (1 mg/kg IV every 6 weeks) or nivolumab (3 mg/kg IV every 2 weeks) plus placebo. Treatment continued for up to 2 years or until disease progression, unacceptable toxic effects, or consent withdrawal. The primary end points were objective response rate and duration of response between treatment arms by blinded independent central review in the population with platinum-refractory recurrent or metastatic disease. These were patients who had recurrent disease less than 6 months after completion of platinum-based chemotherapy (adjuvant or neoadjuvant, or as part of multimodal treatment [chemotherapy, surgery, and/or radiation therapy]). Among the 241 patients (56.7%) with platinum-refractory disease, 159 were assigned to receive nivolumab plus ipilimumab and 82 were assigned to receive nivolumab alone. Among the 184 patients (43.3%) with platinum-eligible disease, 123 were assigned to receive nivolumab plus ipilimumab and 61 were assigned to receive nivolumab alone.[15][Level of evidence B3]

At primary database lock, the objective response rate in the population with platinum-refractory disease was 13.2% (95% CI, 8.4%–19.5%) with nivolumab plus ipilimumab and 18.3% (95% CI, 10.6%–28.4%) with nivolumab alone (odds ratio, 0.68; 95.5% CI, 0.33–1.43; P = .29).

The median duration of response was not reached (NR) in the nivolumab-plus-ipilimumab group (95% CI, 11.0 months–NR) and was 11.1 months (95% CI, 4.1–NR) in the nivolumab-alone group. In the population with platinum-eligible disease, the objective response rate was 20.3% (95% CI, 13.6%–28.5%) with nivolumab plus ipilimumab and 29.5% (95% CI, 18.5%–42.6%) with nivolumab alone.

Among the population with platinum-refractory disease, grade 3 or 4 treatment-related adverse events occurred in 25 of 158 patients (15.8%) who received nivolumab plus ipilimumab and in 12 of 82 patients (14.6%) who received nivolumab alone. Among the population with platinum-eligible disease, grade 3 or 4 treatment-related adverse events occurred in 30 of 122 patients (24.6%) who received nivolumab plus ipilimumab and in 8 of 61 patients (13.1%) who received nivolumab alone.

This trial did not meet its primary end point of objective response rate benefit with first-line nivolumab plus ipilimumab versus nivolumab alone in patients with platinum-refractory recurrent or metastatic head and neck SCC.

Evidence (nivolumab after progression on platinum-based treatment):

A phase III open-label trial included 361 patients with recurrent SCC of the head and neck and disease progression within 6 months after platinum-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (at a dose of 3 mg/kg of body weight) every 2 weeks or standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was OS.[10]

Sources: 10

A phase III open-label trial included 361 patients with recurrent SCC of the head and neck and disease progression within 6 months after platinum-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (at a dose of 3 mg/kg of body weight) every 2 weeks or standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was OS.[10]

The median OS was 7.5 months (95% CI, 5.5–9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0–6.0) in the standard therapy group. OS was statistically significantly longer with nivolumab than with standard therapy (HRdeath, 0.70; 97.73% CI, 0.51–0.96; P = .01). The estimated 1-year survival rate was approximately 19% higher in patients who received nivolumab (36.0%) than in those who received standard therapy (16.6%).[10][Level of evidence A1]

Sources: 10 · Level of evidence A1

There was no statistically significant difference in median PFS between treatment groups. The 6-month PFS rate was 19.7% with nivolumab versus 9.9% with standard therapy.

The response rate was 13.3% in the nivolumab group versus 5.8% in the standard therapy group.

Grade 3 or 4 treatment-related adverse events occurred in 13.1% of the patients in the nivolumab group compared with 35.1% of the patients in the standard therapy group.

Quality-of-life outcomes—including physical, role, and social functioning and pain, sensory, and social contact problems—were stable in the nivolumab group but worse in the standard therapy group. These outcomes were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core Module (QLQ-C30) and the Head and Neck Module (QLQ-H&N35).

In the subgroup of patients with a PD-L1 expression level of 1% or higher, the HRdeath among patients treated with nivolumab versus standard therapy was 0.55 (95% CI, 0.36–0.83). In the subgroup of patients with a PD-L1 expression level lower than 1%, the HR was 0.89 (95% CI, 0.54–1.45; P = .17 for interaction).

A randomized, phase III, superiority study in India evaluated the dose of immune checkpoint inhibitors in the setting of palliative care for patients with advanced head and neck cancer. Low-dose IV nivolumab (20 mg every 3 weeks) was added to a triple metronomic chemotherapy regimen of oral methotrexate (9 mg/m2 once weekly), celecoxib (200 mg twice daily), and erlotinib (150 mg once daily). Notably, this nivolumab dose is less than 10% of the dose recommended by the U.S. Food and Drug Administration and the European Medicines Agency. A total of 151 patients were randomly assigned to receive either triple metronomic chemotherapy alone (n = 75) or triple metronomic chemotherapy with nivolumab (n = 76). The primary end point was 1-year OS.[16]Although the control arm in this study cannot be considered standard care, lower doses of immunotherapy appeared to have some benefit in this setting.[17]

Sources: 16 · 17

A randomized, phase III, superiority study in India evaluated the dose of immune checkpoint inhibitors in the setting of palliative care for patients with advanced head and neck cancer. Low-dose IV nivolumab (20 mg every 3 weeks) was added to a triple metronomic chemotherapy regimen of oral methotrexate (9 mg/m2 once weekly), celecoxib (200 mg twice daily), and erlotinib (150 mg once daily). Notably, this nivolumab dose is less than 10% of the dose recommended by the U.S. Food and Drug Administration and the European Medicines Agency. A total of 151 patients were randomly assigned to receive either triple metronomic chemotherapy alone (n = 75) or triple metronomic chemotherapy with nivolumab (n = 76). The primary end point was 1-year OS.[16]Although the control arm in this study cannot be considered standard care, lower doses of immunotherapy appeared to have some benefit in this setting.[17]

The addition of low-dose nivolumab to triple metronomic chemotherapy improved the 1-year OS rate from 16.3% (95% CI, 8.0%–27.4%) to 43.4% (95% CI, 30.8%–55.3%) (HR, 0.545; 95% CI, 0.362–0.820; P = .0036).[16][Level of evidence A1]

Sources: 16 · Level of evidence A1

The median OS was 6.7 months (95% CI, 5.8–8.1) for patients who received triple metronomic chemotherapy alone and 10.1 months (95% CI, 7.4–12.6) for patients who received triple metronomic chemotherapy with nivolumab (P = .0052).

The rate of grade 3 or higher adverse events was 50% for patients who received triple metronomic chemotherapy alone and 46.1% for patients who received triple metronomic chemotherapy with nivolumab (P = .744).

Salvage after previous combined total laryngectomy and radiation therapy is poor.

For patients · General Information About Laryngeal Cancer

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Prognosis depends on the following:

Sources: Prognosis

The stage of the disease.

Sources: stage

The location and size of the tumor.

Sources: tumor

The grade of the tumor.

Sources: grade

The patient's age, sex, and general health, including whether the patient is anemic.

Sources: anemic

Treatment options depend on the following:

The stage of the disease.

The location and size of the tumor.

Keeping the patient's ability to talk, eat, and breathe as normal as possible.

Whether the cancer has come back (recurred).

Sources: recurred

Smoking tobacco and drinking alcohol decrease the effectiveness of treatment for laryngeal cancer. Patients with laryngeal cancer who continue to smoke and drink are less likely to be cured and more likely to develop a second tumor. After treatment for laryngeal cancer, frequent and careful follow-up is important.

Sources: alcohol · cured · follow-up

For patients · Stages of Laryngeal Cancer

After surgery, the stage of the cancer may change and more treatment may be needed.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

If the cancer is removed by surgery, a pathologist will examine a sample of the cancer tissue under a microscope. Sometimes, the pathologist’s review will result in a change to the stage of the cancer and more treatment after surgery.

Sources: surgery · pathologist · tissue · microscope

For patients · Stages of Laryngeal Cancer

Laryngeal cancer can recur (come back) after it has been treated.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The cancer may come back in the larynx or in other parts of the body, such as lungs, liver, or bone. It is most likely to come back in the first 2 to 3 years.

Sources: larynx

For patients

Treatment Option Overview

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

There are different types of treatment for patients with laryngeal cancer.

The following types of treatment are used:

The following types of treatment are used:

Radiation therapy

Surgery

Chemotherapy

Immunotherapy

New types of treatment are being tested in clinical trials.

New types of treatment are being tested in clinical trials.

Targeted therapy

Radiosensitizers

Treatment for laryngeal cancer may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with laryngeal cancer.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Different types of treatment are available for patients with laryngeal cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: laryngeal cancer · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: Radiation therapy · x-rays · radiation · cells · External radiation therapy

Radiation therapy may work better in patients who have stopped smoking before beginning treatment. External radiation therapy to the thyroid or the pituitary gland may change the way the thyroid gland works. A blood test to check the thyroid hormone level in the body may be done before and after therapy to make sure the thyroid gland is working properly.

Sources: thyroid · pituitary gland · blood test · thyroid hormone · therapy

Hyperfractionated radiation therapy may be used to treat laryngeal cancer. Hyperfractionated radiation therapy is radiation treatment in which a smaller than usual total daily dose of radiation is divided into two doses and the treatments are given twice a day. Hyperfractionated radiation therapy is given over the same period of time (days or weeks) as standard radiation therapy. New types of radiation therapy are being studied in the treatment of laryngeal cancer.

Sources: Hyperfractionated radiation therapy · dose

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Surgery (removing the cancer in an operation) is a common treatment for all stages of laryngeal cancer. The following surgical procedures may be used:

Sources: Surgery

Cordectomy: Surgery to remove the vocal cords only.

Sources: Cordectomy · vocal cords

Supraglottic laryngectomy: Surgery to remove the supraglottis only.

Sources: Supraglottic laryngectomy · supraglottis

Hemilaryngectomy: Surgery to remove half of the larynx (voice box). A hemilaryngectomy saves the voice.

Sources: Hemilaryngectomy · larynx

Partial laryngectomy: Surgery to remove part of the larynx (voice box). A partial laryngectomy helps keep the patient's ability to talk.

Sources: Partial laryngectomy

Total laryngectomy: Surgery to remove the whole larynx. During this operation, a hole is made in the front of the neck to allow the patient to breathe. This is called a tracheostomy.

Sources: Total laryngectomy · tracheostomy

Thyroidectomy: The removal of all or part of the thyroid gland.

Sources: Thyroidectomy

Laser surgery: A surgical procedure that uses a laser beam (a narrow beam of intense light) as a knife to make bloodless cuts in tissue or to remove a surface lesion such as a tumor in the larynx.

Sources: Laser surgery · laser beam · tissue · lesion · tumor

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · adjuvant therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: drugs · injected · vein · systemic chemotherapy

For more information, see Drugs Approved for Head and Neck Cancer. Laryngeal cancer is a type of head and neck cancer.

Sources: Drugs Approved for Head and Neck Cancer · head and neck cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. This cancer treatment is a type of biologic therapy.

Sources: Immunotherapy · immune system · biologic therapy

PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Nivolumab and pembrolizumab are types of PD-1 inhibitors used to treat metastatic or recurrent laryngeal cancer.

Sources: PD-1 · PD-L1 · therapy · protein · T cells · immune responses · Nivolumab · pembrolizumab · metastatic · recurrent

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Targeted therapy

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.

Sources: Targeted therapy

Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Cetuximab is being studied in the treatment of laryngeal cancer.

Sources: Monoclonal antibodies · antibodies · infusion · toxins · radioactive · Cetuximab

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Radiosensitizers

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Radiosensitizers are drugs that make tumor cells more sensitive to radiation therapy. Combining radiation therapy with radiosensitizers may kill more tumor cells.

Sources: Radiosensitizers

For patients · Treatment Option Overview

Treatment for laryngeal cancer may cause side effects.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Stage I Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed stage I laryngeal cancer depends on where cancer is found in the larynx.

Sources: diagnosed · stage I laryngeal cancer · cancer · larynx

If cancer is in the supraglottis, treatment may include the following:

Sources: supraglottis

Radiation therapy.

Sources: Radiation therapy

Supraglottic laryngectomy.

Sources: Supraglottic laryngectomy

If cancer is in the glottis, treatment may include the following:

Sources: glottis

Radiation therapy.

Laser surgery.

Sources: Laser surgery

Cordectomy.

Sources: Cordectomy

Partial laryngectomy, hemilaryngectomy, or total laryngectomy.

Sources: Partial laryngectomy · hemilaryngectomy · total laryngectomy

If cancer is in the subglottis, treatment may include the following:

Sources: subglottis

Radiation therapy with or without surgery.

Sources: surgery

Surgery alone.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage II Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed stage II laryngeal cancer depends on where cancer is found in the larynx.

Sources: diagnosed · stage II laryngeal cancer · cancer · larynx

If cancer is in the supraglottis, treatment may include the following:

Sources: supraglottis

Radiation therapy to the tumor and nearby lymph nodes.

Sources: Radiation therapy · tumor · lymph nodes

Supraglottic laryngectomy which may be followed by radiation therapy.

Sources: Supraglottic laryngectomy

If cancer is in the glottis, treatment may include the following:

Sources: glottis

Radiation therapy.

Laser surgery.

Sources: Laser surgery

Partial laryngectomy, hemilaryngectomy, or total laryngectomy.

Sources: Partial laryngectomy · hemilaryngectomy · total laryngectomy

If cancer is in the subglottis, treatment may include the following:

Sources: subglottis

Radiation therapy with or without surgery.

Sources: surgery

Surgery alone.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed stage III laryngeal cancer depends on where cancer is found in the larynx.

Sources: diagnosed · stage III laryngeal cancer · cancer · larynx

If cancer is in the supraglottis, treatment may include the following:

Sources: supraglottis

Chemotherapy and radiation therapy given together

Sources: Chemotherapy · radiation therapy

Chemotherapy followed by chemotherapy and radiation therapy given together. Laryngectomy may be done if cancer remains.

Sources: Laryngectomy

Radiation therapy alone for patients who cannot be treated with chemotherapy and surgery.

Sources: surgery

Surgery, which may be followed by radiation therapy.

If cancer is in the glottis, treatment may include the following:

Sources: glottis

Chemotherapy and radiation therapy given together.

Chemotherapy followed by chemotherapy and radiation therapy given together. Laryngectomy may be done if cancer remains.

Radiation therapy alone for patients who cannot be treated with chemotherapy and surgery.

Surgery, which may be followed by radiation therapy.

A clinical trial of radiation therapy alone compared with radiation and targeted therapy (cetuximab).

A clinical trial of immunotherapy, chemotherapy, radiosensitizers, or radiation therapy.

Sources: radiosensitizers

If cancer is in the subglottis, treatment may include the following:

Sources: subglottis

Laryngectomy plus total thyroidectomy and removal of lymph nodes in the throat, usually followed by radiation therapy.

Sources: thyroidectomy · lymph nodes · throat

Radiation therapy followed by surgery if cancer comes back in the same area.

Radiation therapy alone for patients who cannot be treated with chemotherapy and surgery.

Chemotherapy followed by chemotherapy and radiation therapy given together. Laryngectomy may be done if cancer remains.

A clinical trial of radiation therapy alone compared with radiation and targeted therapy (cetuximab).

A clinical trial of immunotherapy, chemotherapy, radiosensitizers, or radiation therapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage IV Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed stage IVA, IVB, and IVC laryngeal cancer depends on where cancer is found in the larynx.

Sources: diagnosed · stage IVA · IVB · IVC laryngeal cancer · cancer · larynx

If cancer is in the supraglottis or glottis, treatment may include the following:

Sources: supraglottis · glottis

Chemotherapy and radiation therapy given together.

Sources: Chemotherapy · radiation therapy

Chemotherapy followed by chemotherapy and radiation therapy given together. Laryngectomy may be done if cancer remains.

Sources: Laryngectomy

Radiation therapy alone for patients who cannot be treated with chemotherapy and surgery.

Sources: surgery

Surgery followed by radiation therapy. Chemotherapy may be given with the radiation therapy.

A clinical trial of radiation therapy alone compared with radiation and targeted therapy (cetuximab).

Sources: clinical trial · cetuximab

A clinical trial of immunotherapy, chemotherapy, radiosensitizers, or radiation therapy.

Sources: radiosensitizers

If cancer is in the subglottis, treatment may include the following:

Sources: subglottis

Laryngectomy plus total thyroidectomy and removal of lymph nodes in the throat, usually followed by radiation therapy with or without chemotherapy.

Chemotherapy and radiation therapy given together.

A clinical trial of radiation therapy alone compared with radiation and targeted therapy (cetuximab).

A clinical trial of immunotherapy, chemotherapy, radiosensitizers, or radiation therapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Metastatic and Recurrent Laryngeal Cancer

Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of metastatic and recurrent laryngeal cancer may include the following:

Sources: metastatic · recurrent · laryngeal cancer

Surgery with or without radiation therapy.

Sources: Surgery · radiation therapy

Radiation therapy.

Chemotherapy.

Sources: Chemotherapy

Immunotherapy with pembrolizumab or nivolumab.

Sources: Immunotherapy · pembrolizumab · nivolumab

A clinical trial of a new treatment.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx

NCT00002496 · COMPLETED · phase3

Head and Neck Cancer

ClinicalTrials.gov record

High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer

NCT00002555 · COMPLETED · phase3

Head and Neck Cancer

ClinicalTrials.gov record

Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

NCT00002670 · COMPLETED · phase3

Head and Neck Cancer

ClinicalTrials.gov record

Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00771641 · COMPLETED · phase3

Head and Neck Cancer

ClinicalTrials.gov record

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

NCT00956007 · ACTIVE NOT RECRUITING · phase3

Head and Neck Cancer

ClinicalTrials.gov record

Celebrex (Celecoxib) Treatment of Laryngeal Papilloma

NCT00592319 · TERMINATED · phase2

Laryngeal Papilloma

ClinicalTrials.gov record

Phase II Trial Evaluating Elimination of Radiation Therapy

NCT00593840 · ACTIVE NOT RECRUITING · phase2

Cancer of the Larynx

ClinicalTrials.gov record

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

NCT00599131 · TERMINATED · phase2

Cancer of Larynx

ClinicalTrials.gov record

Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis

NCT00661570 · TERMINATED · na

Total Laryngectomy

ClinicalTrials.gov record

Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract

NCT00721539 · TERMINATED · na

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Cancers

ClinicalTrials.gov record

Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis

NCT00743262 · COMPLETED · phase1, phase2

Total Laryngectomy

ClinicalTrials.gov record

Clinical Feasibility of New Tracheoesophageal Puncture Set

NCT01045057 · COMPLETED · na

Larynx Cancer

ClinicalTrials.gov record

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

NCT01633541 · COMPLETED · phase2

Laryngeal Cancer

ClinicalTrials.gov record

Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function

NCT02633540 · TERMINATED · phase2

Laryngeal Neoplasms

ClinicalTrials.gov record

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

NCT03529422 · ACTIVE NOT RECRUITING · phase2

Larynx, Lip, Oral Cancer, Digestive Organs--Diseases

ClinicalTrials.gov record

Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer

NCT03548285 · COMPLETED · na

Glottic Carcinoma

ClinicalTrials.gov record

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

NCT04030455 · ACTIVE NOT RECRUITING · phase2

Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8

ClinicalTrials.gov record

A Novel Approach for Thyroplasty Type 1, With Prolene Mesh. A Prospective Study.

NCT04458818 · COMPLETED · na

Vocal Cord Paralysis, Phonasthenia, Presbylarynges, Idiopathic Vocal Cord Paralysis, Ca Larynx

ClinicalTrials.gov record

Validation and Cross-cultural Adaptation of Croatian SECEL Questionnaire

NCT05346237 · COMPLETED · Phase not reported

Larynx Neoplasm, Laryngectomy; Status, Communication, Quality of Life

ClinicalTrials.gov record

Phonatory Movement of the Pharyngoesophageal Mucosa in Laryngectomy Patients

NCT05561920 · COMPLETED · Phase not reported

Larynx Cancer, Laryngectomy; Status

ClinicalTrials.gov record

Disease and treatment settings

Laryngeal Cancer

Disease and treatment setting

Laryngeal Cancer

locally advanced Laryngeal Cancer

Disease and treatment setting

Surgery Followed by Postoperative Radiation Therapy (PORT) With or Without Chemotherapy for Patients With Locally Advanced Disease

recurrent Laryngeal Cancer

Disease and treatment setting

Treatment of Metastatic and Recurrent Laryngeal Cancer

Stage I Laryngeal Cancer

Disease and treatment setting

Treatment of Stage I Laryngeal Cancer

Stage II Laryngeal Cancer

Disease and treatment setting

Treatment of Stage II Laryngeal Cancer

Stage III Laryngeal Cancer

Disease and treatment setting

Treatment of Stage III Laryngeal Cancer

Stage IV Laryngeal Cancer

Disease and treatment setting

Treatment of Stage IV Laryngeal Cancer